BRPI0412282A - imunidade especìfica e não-especìfica induzida de dsrna em crustáceos e outros invertebrados, e veìculos de bioliberação para uso nestes - Google Patents

imunidade especìfica e não-especìfica induzida de dsrna em crustáceos e outros invertebrados, e veìculos de bioliberação para uso nestes

Info

Publication number
BRPI0412282A
BRPI0412282A BRPI0412282-8A BRPI0412282A BRPI0412282A BR PI0412282 A BRPI0412282 A BR PI0412282A BR PI0412282 A BRPI0412282 A BR PI0412282A BR PI0412282 A BRPI0412282 A BR PI0412282A
Authority
BR
Brazil
Prior art keywords
dsrna
specific
invertebrates
crustacean
methods
Prior art date
Application number
BRPI0412282-8A
Other languages
English (en)
Inventor
Paul Gross
Gregory Warr
Robert Chapman
Craig Browdy
Javier Robalino
Original Assignee
Musc Found For Res Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Musc Found For Res Dev filed Critical Musc Found For Res Dev
Publication of BRPI0412282A publication Critical patent/BRPI0412282A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)

Abstract

"IMUNIDADE ESPECìFICA E INESPECìFICA INDUZIDA POR dsRNA EM CRUSTáCEOS E OUTROS INVERTEBRADOS E VEìCULOS DE BIOLIBERAçãO PARA USO NESTES". São fornecidos métodos para a indução de respostas imunes sistêmicas, inespecíficas, e/ou com especificidade de seqüência em invertebrados, por exemplo, invertebrados marinhos, tais como moluscos, poríferos, ctenóforos, equinodermos, vermes marinhos, cnidários e, preferivelmente, crustáceos, pela administração de pelo menos um dsRNA, que confere imunidade contra um patógeno ou que modula a expressão gênica que afeta o crescimento, reprodução e saúde geral ou 'robustez'. Também são fornecidos métodos de identificação de genes de invertebrados, por exemplo, genes de crustáceos, cuja expressão esteja envolvida na indução de respostas imunes inespecíficas (sistêmicas) contra patógenos. Também são revelados sistemas de liberação e métodos preferidos para a administração de forma estável de pelo menos um dsRNA a um crustáceo, através do qual o dsRNA é administrado por meio de injeção, imersão, em uma ração ou meio nutriente ou contido em um microorganismo, por exemplo, levedura ou microalga, que expresse o referido dsRNA e seja passível de ingestão pelo referido crustáceo, por exemplo, um camarão.
BRPI0412282-8A 2003-07-02 2004-07-02 imunidade especìfica e não-especìfica induzida de dsrna em crustáceos e outros invertebrados, e veìculos de bioliberação para uso nestes BRPI0412282A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48453103P 2003-07-02 2003-07-02
US49860303P 2003-08-29 2003-08-29
US50571403P 2003-09-25 2003-09-25
US56429504P 2004-04-22 2004-04-22
PCT/US2004/021271 WO2005005613A2 (en) 2003-07-02 2004-07-02 Dsrna induced specific and non-specific immunity in crustaceans and other invertebrates and biodelivery vehicles for use therein

Publications (1)

Publication Number Publication Date
BRPI0412282A true BRPI0412282A (pt) 2006-09-19

Family

ID=34069336

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412282-8A BRPI0412282A (pt) 2003-07-02 2004-07-02 imunidade especìfica e não-especìfica induzida de dsrna em crustáceos e outros invertebrados, e veìculos de bioliberação para uso nestes

Country Status (4)

Country Link
US (1) US8633028B2 (pt)
JP (2) JP5183064B2 (pt)
BR (1) BRPI0412282A (pt)
WO (1) WO2005005613A2 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1807522B1 (en) 2004-10-21 2013-11-20 Venganza Inc. Methods and materials for conferring resistance to pests and pathogens of plants
CN100485036C (zh) * 2005-09-19 2009-05-06 中国科学院海洋研究所 一种中国明对虾抗菌蛋白基因及重组表达和应用
FR2908136A1 (fr) * 2006-11-07 2008-05-09 Ifremer Utilisation de peptides antimicrobiens comme marqueurs de resistance aux infections bacteriennes chez les crevettes peneides
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
FR2926367B1 (fr) * 2008-01-10 2013-01-04 Novaleads Procede fluorimetrique pour evaluer l'influence d'une condition sur un echantillon biologique et ses applications.
US9049850B2 (en) * 2008-02-04 2015-06-09 Ben-Gurion University Of The Negev Research And Development Authority Insulin-like gene of prawns and uses thereof
US8440878B2 (en) 2008-02-04 2013-05-14 Ben-Gurion University Of The Negev Research And Development Authority Insulin-like gene in prawns and uses thereof
CN101617638B (zh) * 2008-07-04 2011-08-31 中国科学院海洋研究所 一种三疣梭子蟹抗病品系的构建方法
MX352992B (es) 2009-05-05 2017-12-15 Beeologics Inc Prevencion y tratamiento de la enfermedad de nosema en abejas.
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
CA2820536A1 (en) * 2010-10-22 2012-04-26 Donald Danforth Plant Science Center Control of pathogens and parasites
US10004797B2 (en) 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
WO2012058072A1 (en) 2010-10-27 2012-05-03 Harrisvaccines, Inc Method of rapidly producing vaccines for animals
US8822427B2 (en) 2010-10-27 2014-09-02 Harrisvaccines Methods and compositions to protect aquatic invertebrates from disease
CN102816815A (zh) * 2012-03-30 2012-12-12 浙江海洋学院 重组抗菌肽rCrustinI的酵母发酵生产方法
US9133461B2 (en) * 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
US9127274B2 (en) * 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
CN102787073B (zh) * 2012-07-13 2014-05-14 苏州大学 一种构建转基因家蚕微孢子虫的方法
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
JP6668236B2 (ja) 2013-07-19 2020-03-18 モンサント テクノロジー エルエルシー Ｌｅｐｔｉｎｏｔａｒｓａ防除用組成物及びその方法
SG11201602631XA (en) 2013-10-04 2016-05-30 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of the alas1 gene
BR112016022711A2 (pt) 2014-04-01 2017-10-31 Monsanto Technology Llc composições e métodos para controle de pragas de inseto
AU2015296700B2 (en) 2014-07-29 2021-10-21 Monsanto Technology Llc Compositions and methods for controlling insect pests
US10968449B2 (en) 2015-01-22 2021-04-06 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
WO2017009838A1 (en) * 2015-07-14 2017-01-19 Transalgae Israel Ltd. Transgenic microalgae and use thereof as a feed for delivery of interfering rna molecules
SG11201804729RA (en) 2015-12-07 2018-07-30 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder
WO2017180616A1 (en) * 2016-04-11 2017-10-19 Microsynbiotix, Ltd. Dna constructs for manufacturing bio-therapeutic polypeptides for use in animal vaccines and therapeutics
MX2018013122A (es) 2016-04-26 2019-03-28 Viaqua Therapeutics Ltd Composiciones y procedimientos para tratar infecciones viricas en gambas.
TWI605816B (zh) * 2016-11-02 2017-11-21 國立屏東科技大學 針對酪氨酸羥化酶之雙股ｒｎａ的用途
US11446339B2 (en) 2017-03-31 2022-09-20 Pebble Labs Inc. System for the biocontrol of white spot syndrome virus (WSSV) in aquaculture
AU2018243858A1 (en) 2017-03-31 2019-10-10 Pebble Labs Usa Inc. Novel system for the biocontrol of pathogens in aquaculture and other animal systems
CN106973864A (zh) * 2017-04-25 2017-07-25 遵义医学院 一种适用于白背飞虱注射法rna干扰实验的饲养装置及其使用方法
CN106942162A (zh) * 2017-04-25 2017-07-14 遵义医学院 一种适用于白背飞虱饲喂法rna干扰实验的装置及其使用方法
EP3664616A4 (en) * 2017-08-07 2021-08-11 Pebble Labs, Inc. SYSTEMS AND METHODS FOR CONTROLLING ACUTE HEPATOPANCREATIC NECROSIS DISEASE
CN109479899A (zh) * 2018-09-30 2019-03-19 中国农业科学院植物保护研究所 鞘翅目金龟类昆虫rna干扰的方法
CN109652420B (zh) * 2019-01-22 2022-06-14 汕头大学 一种高效抵抗WSSV的siRNA分子wsv147在制备抗WSSV制剂的应用
CN111304146B (zh) * 2020-03-11 2022-06-17 浙江省淡水水产研究所 一种促中华绒螯蟹造血组织发育免疫增强剂的筛选模型构建方法
CN113502337B (zh) * 2021-07-13 2022-03-22 华中农业大学 一种提高克氏原螯虾抗病能力的snp分子标记及应用
US20250108067A1 (en) 2021-11-09 2025-04-03 Viaqua Therapeutics Ltd. Compositions for aquaculturing
WO2024033948A1 (en) * 2022-08-11 2024-02-15 Karyotica Biologicals Private Limited Chimeric dna targeted to white spot syndrome
CN115589972B (zh) * 2022-09-07 2023-10-20 南京市水产科学研究所 一种基于池塘改造的螺蛳河蟹接力生态养殖方法
WO2024142041A1 (en) * 2022-12-29 2024-07-04 Viaqua Therapeutics Ltd. Compositions and methods for aquatic microsporidian infection
WO2024238491A2 (en) * 2023-05-12 2024-11-21 Redux Bio, Inc. Engineered microalgae and use in aquaculture
WO2025238646A1 (en) * 2024-05-17 2025-11-20 Viaqua Therapeutics Ltd. Stabilized chitosan-rna composition with magnesium
CN118600034A (zh) * 2024-06-21 2024-09-06 中国科学院南海海洋研究所 一种南美白对虾亚硝酸盐胁迫相关基因的snp标记、检测引物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270175A (en) * 1991-07-12 1993-12-14 Dna Plant Technology Corporation Methods and compositions for producing metabolic products for algae
GB9307408D0 (en) * 1993-04-08 1993-06-02 Danisco Transgenic plants
JPH09201196A (ja) * 1996-01-25 1997-08-05 Koyu Kaku 白斑症候群関連バキュロウイルスの同定、精製および検出
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
BRPI9908967B1 (pt) * 1998-03-20 2017-05-30 Benitec Australia Ltd processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula de planta
KR20000075076A (ko) 1999-05-28 2000-12-15 최태진 형질전환된 미세조류를 이용하여 외래 단백질을 생산하는 방법
BR0012919A (pt) 1999-08-03 2002-04-23 Akzo Nobel Nv Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
EP1235842A4 (en) * 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) * 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US6908616B2 (en) 2000-09-15 2005-06-21 Akzo Nobel N.V. Antigenic proteins of shrimp white spot syndrome virus and uses thereof
US20020164706A1 (en) * 2001-01-30 2002-11-07 Huang Lisa L. High level promoters from cyanobacteria
US6440466B1 (en) * 2001-02-21 2002-08-27 Council Of Scientific & Industrial Research Composition for treating white spot syndrome virus (WSSV) infected tiger shrimp penaeus monodon and a process for preparation thereof
AUPR621501A0 (en) * 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US20040266708A1 (en) * 2002-01-29 2004-12-30 Paul Diamond Regulation of polynucleic acid activity and expression
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
JP4731907B2 (ja) * 2002-09-16 2011-07-27 アドバンスド バイオニュートリション コーポレーション 受動免疫のための蛋白質およびペプチド発現
GB0306715D0 (en) 2003-03-24 2003-04-30 Novartis Ag Organic compounds
MXPA06009005A (es) 2004-02-06 2007-03-26 Advanced Bionutrition Corp Interferencia mediada por acido ribonucleico para el control de enfermedad en animales terrestres y de acuacultura.
US8716462B2 (en) * 2006-01-27 2014-05-06 Carnegie Institution Of Washington Levels and/or sustainability of DNA-based gene expression
JP2008063302A (ja) * 2006-09-11 2008-03-21 Fisheries Research Agency クルマエビ属ホワイトスポット病用経口ワクチン
JP2008169131A (ja) * 2007-01-10 2008-07-24 Univ Of Miyazaki 甲殻類急性ウイルス血症に対するｄｎａワクチン
WO2009016647A1 (en) * 2007-08-01 2009-02-05 Council Of Scientific & Industrial Research Pyrrolo [2,1-c][1, 4] benzodiazepine-glycoside prodrugs useful as a selective anti tumor agent

Also Published As

Publication number Publication date
JP5183064B2 (ja) 2013-04-17
WO2005005613A2 (en) 2005-01-20
JP2012036187A (ja) 2012-02-23
JP2007530414A (ja) 2007-11-01
US8633028B2 (en) 2014-01-21
WO2005005613A3 (en) 2005-06-02
US20050080032A1 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
WO2005005613A3 (en) Dsrna induced specific and non-specific immunity in crustaceans and other invertebrates and biodelivery vehicles for use therein
Wrobel et al. Overcoming fish defences: the virulence factors of Yersinia ruckeri
Vollmer et al. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll‐like receptor 9 dependent T helper type 2 biased immune stimulation
Gram et al. Inhibition of Vibrio anguillarum by Pseudomonas fluorescens AH2, a possible probiotic treatment of fish
Wolf et al. Evidence for the role of a siderophore in promoting Vibrio anguillarum infections
EP0876150A4 (en) NON-TOXIC MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA
CA2477371A1 (en) Immunostimulatory agent comprising a biomass of methanotrophic bacterium
Liu et al. Infectious gastroenteritis caused by Vibrio harveyi (V. carchariae) in cultured red drum, Sciaenops ocellatus
RU95100750A (ru) Штамм bifidobacterium breve 79-119, используемый для получения бактерийных лечебно-профилактических бифидосодержащих препаратов
Kashulin et al. Cold‐water vibriosis. The current status of knowledge
Vosbeck et al. Effects of low concentrations of antibiotics on Escherichia coli adhesion
SE9801090L (sv) Odlingsmedium för animalceller
Chen et al. Tapping Chlorella vulgaris potential for enhanced growth, immunity, digestion, microbiota, and immunometabolism in Litopenaeus vannamei feeding across varied salinities
DE69233653D1 (de) Herstellung gegen sclerotinia sclerotiorum resistenter pflanzendurch einführung eines für oxalatoxydase kodierenden gens
WO2013084169A3 (en) Novel broth medium and blood-free solid media for the culture of the fish pathogen piscirickettsia salmonis
Austin Progress in understanding the fish pathogen Aeromonas salmonicida
Tu et al. Effect of temperature on survival and growth of infectious pancreatic necrosis virus
ES2027374T3 (es) Perfeccionamientos en productos de tipo probiotico.
CN105002280A (zh) 弧菌的荧光定量pcr检测方法
KR960003592A (ko) 광합성 세균을 포함하는 어류양식용 인공사료 및 이의 제조방법
CN102839216B (zh) 用于哈氏弧菌的环介导恒温扩增快速检测试剂盒及方法
Wiström et al. A case of acute cholecystitis due to Aeromonas sobria and Hafnia alvei from northern Europe
MXPA05004732A (es) Enema de volumen grande.
Leifson Mixed polar and peritrichous flagellation of marine bacteria
MD3170G2 (ro) Procedeu de cultivare a infuzorilor Paramecium caudatum

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O ARTIGO 10 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.